Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence patterns and trends of chordoma in the United States: a population-based analysis of over 6,000 cases.

Journal of bone oncology·2026
Same author

Disruption of CTCF binding by germline non-coding variants in <i>CDKN2B</i> suppress <i>CDKN2A</i> expression and predispose to melanoma.

medRxiv : the preprint server for health sciences·2026
Same author

Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals.

JAMA dermatology·2026
Same author

Epstein-Barr-virus-specific functional antibody signatures in the context of nasopharyngeal carcinoma development.

Med (New York, N.Y.)·2025
Same author

Immunotherapy Resistance in Lethal Prepubescent Spitz Melanoma With <i>TERT</i> Promoter Variant.

JCO precision oncology·2025
Same author

Clinicopathologic Features, Management, and Outcomes Of Pediatric CRTC1::TRIM11 and MED15::ATF1 Tumors With Spitzoid Morphology: A Case Series.

Pediatric blood & cancer·2025

Related Experiment Video

Updated: Jul 10, 2026

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Genetic testing for melanoma predisposition: current challenges.

Meg R Gerstenblith1, Alisa M Goldstein, Margaret A Tucker

  • 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20852-7236, USA.

Cancer Nursing
|November 21, 2007
PubMed
Summary

Early melanoma detection is crucial. Predictive genetic testing for CDKN2A mutations is not recommended due to low detection rates and unclear interpretation, but nurses play a key role in risk assessment and surveillance.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Experiment Videos

Last Updated: Jul 10, 2026

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Area of Science:

  • Oncology
  • Genetics
  • Dermatology

Background:

  • Cutaneous malignant melanoma arises from complex genetic, host, and environmental interactions.
  • Melanoma is a common cancer in the US, with mortality linked to diagnosis stage.
  • Early detection and risk factor identification are vital for melanoma surveillance.

Purpose of the Study:

  • To evaluate the role of CDKN2A and CDK4 genes in melanoma development.
  • To assess the utility of predictive genetic testing for CDKN2A mutations.
  • To define the role of oncology nurses in melanoma risk management.

Main Methods:

  • Review of current understanding of CDKN2A and CDK4 gene functions in melanoma.
  • Analysis of the limitations and recommendations regarding predictive genetic testing for CDKN2A mutations.
  • Identification of key responsibilities for oncology nurses in melanoma patient care.

Main Results:

  • The functions of CDKN2A and CDK4 in melanoma are not fully understood.
  • Predictive genetic testing for CDKN2A mutations is currently not recommended outside research settings.
  • Oncology nurses are essential in identifying high-risk individuals and promoting surveillance.

Conclusions:

  • Predictive genetic testing for CDKN2A mutations has limitations in clinical practice.
  • Oncology nurses are pivotal in melanoma prevention, early detection, and patient education.
  • Risk assessment and surveillance programs are crucial for managing melanoma risk.